Drug combination for advanced soft tissue sarcoma after prior treatment
Part of Bones, joints & muscles, Cancer clinical trials.
This trial tests two newer drugs—surufatinib, which cuts off blood supply to tumors, and envafolimab, which helps your immune system attack cancer cells—for people with advanced soft tissue sarcoma who have already tried other treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a type of soft tissue sarcoma (like leiomyosarcoma, synovial sarcoma, or angiosarcoma) that has spread or cannot be removed by surgery.
- You must have already tried at least one prior treatment for your sarcoma, and it either didn't work or caused intolerable side effects.
- You need to be able to provide a tumor tissue sample (from a recent or stored biopsy).
- Your overall health should be fairly good (able to do daily activities, ECOG score 0-2).
- You cannot have certain heart conditions, uncontrolled high blood pressure, bleeding problems, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (envafolimab) combined with two chemotherapy drugs (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior treatment. The goal is to see if this combination is safe and effective.
This trial is testing whether a combination of two drugs—a targeted therapy (surufatinib) and an immunotherapy (envafolimab)—can help people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. Researchers will also use a person's genetic information and scans to see if they can predict who will benefit the most.
This Phase 1/2 trial tests whether combining radiation with two targeted/immune medicines can shrink or control high-risk soft tissue sarcoma and improve outcomes. It may help patients whose tumors are large, hard to fully remove, or have come back after prior treatment.
This study tests a combination of two drugs (anlotinib and bempegaldesleukin) plus standard chemotherapy and radiation for people with advanced soft tissue sarcoma that has spread or can't be removed. The goal is to see if this combination helps shrink tumors and control the cancer.
This trial tests a combination of three drugs—liposomal irinotecan, temozolomide, and bevacizumab—for people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery and has not responded to previous treatments. The goal is to see if this combination can help control the cancer.
This trial tests a combination of targeted therapy (Surufatinib) and chemotherapy (Temozolomide and S-1) as a first treatment for advanced neuroendocrine tumors that have not been treated before. It aims to see if this drug combo is safe and effective.
Hear when a new Efficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.